Metsera Raises $215M to Propel Obesity Treatment Trials Amid Promising Results

Metsera is strategically focusing its efforts on obesity treatments by advancing its portfolio of GLP-1 receptor agonists, particularly the promising MET-097i[1][2]. Since its launch, the biotech startup has raised over $500 million, including a recent $215 million Series B funding. This enables them to push forward with a Phase II trial following a Phase I/II trial where MET-097i showed a body weight reduction of 7.5%[1][3]. Besides MET-097i, Metsera is investing in additional obesity treatment candidates, including MET-233i, an injectable amylin analog, and an oral GLP-1 peptide MET-002[2]. Their collaboration with Amneal Pharmaceuticals supports their global expansion plans[1][3].